B-701
Phase 1Small molecule
B-701 is one of 43 small molecule programs targeting Transitional Cell Carcinoma. It is currently in Phase 1.
1
Indications
2
Total Trials
0
Active Trials
42
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
48 competitors in Transitional Cell Carcinoma
#DrugCompanyPhaseTrials
1Taxol
TevaApproved
Eloxatin
TevaApproved
Adrucil
EElorac, Inc.
Approved
Ifex
BBaxter Healthcare Corporation
Approved
Mitosol
UUroGen Pharma Ltd.
Approved
Trexall
Alnylam PharmaceuticalsPhase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Gemzar
GGynecologic Oncology Group
Phase 3
Adriamycin
GGynecologic Oncology Group
Phase 3
Velban
EEastern Cooperative Oncology Group
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Locally Advanced1 trial
Transitional Cell Carcinoma1 trial
Ph 1B B-701 in Combination With Pembrolizumab in Metastatic Transitional Cell Carcinoma of the Urothelial Tract
Terminated·—·Phase 1·NCT02925533·1 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for B-701. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- RRainier Therapeutics